Cardiol TherapeuticsCRDL
Market Cap: $128M
About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Employees: 17
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
4,883% more call options, than puts
Call options by funds: $897K | Put options by funds: $18K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
14% more funds holding
Funds holding: 35 [Q1] → 40 (+5) [Q2]
2.25% less ownership
Funds ownership: 10.07% [Q1] → 7.81% (-2.25%) [Q2]
8% less capital invested
Capital invested by funds: $11.7M [Q1] → $10.8M (-$908K) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Roth MKM Jason Wittes 63% 1-year accuracy 12 / 19 met price target | 446%upside $10 | Buy Initiated | 26 Jun 2024 |
HC Wainwright & Co. Vernon Bernardino 39% 1-year accuracy 12 / 31 met price target | 392%upside $9 | Buy Reiterated | 14 Jun 2024 |